| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 672.95% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy |
| 07/10/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/13/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/02/2023 | 672.95% | HC Wainwright & Co. | $7 → $16 | Reiterates | → Buy |
| 05/05/2023 | 238.16% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/26/2023 | 238.16% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 03/20/2023 | -27.54% | Maxim Group | → $1.5 | Upgrades | Hold → Buy |
| 01/31/2023 | 383.09% | Roth Capital | → $10 | Reinstates | → Buy |
| 10/12/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 06/28/2021 | 383.09% | Roth Capital | → $10 | Initiates Coverage On | → Buy |
| 03/10/2021 | 286.47% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
What is the target price for Panbela Therapeutics (PBLA)?
The latest price target for Panbela Therapeutics (NASDAQ: PBLA) was reported by HC Wainwright & Co. on July 24, 2023. The analyst firm set a price target for $16.00 expecting PBLA to rise to within 12 months (a possible 672.95% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
The latest analyst rating for Panbela Therapeutics (NASDAQ: PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $16.00 to $16.00. The current price Panbela Therapeutics (PBLA) is trading at is $2.07, which is out of the analyst's predicted range.